On behalf of GlaxoSmithKline (GSK) in 2013, we produced this report that assesses over 900 healthcare programmes for their suitability for investment to scale up and replicate elsewhere. It identifies significant opportunities for commercial organisations to establish strategic partnerships with a number of promising healthcare delivery models in order to drive scale, profitability and impact.